The Medicines and Healthcare products Regulatory Agency (MHRA)
has granted a marketing authorisation for the
medicine brensocatib (Brinsupri) to treat patients
12 years and older with non-cystic fibrosis bronchiectasis
(NCFB) who have experienced two or more flare-ups or
worsening of symptoms in the past 12 months.
NCFB is a chronic, long-term condition where the
airways of the lungs are damaged, causing a cough with mucus
production. It can affect anybody but is more common in
older adults.
Brensocatib works by targeting a protein called
dipeptidyl peptidase 1 (DPP1), which is involved in the process
that causes inflammation in the lungs. By blocking the activity
of this protein, the medicine prevents flare-ups in the lungs and
may improve some symptoms of NCFB.
Beach, MHRA Executive
Director, Healthcare Quality and Access,
said:
“This is the first medicine licensed in the UK that
specifically treats patients living with non-cystic fibrosis
bronchiectasis.
“As with any medicine, the MHRA will keep the safety and
effectiveness of brensocatib under close review.”
Brensocatib is available as a tablet to be taken by mouth
once a day.
The most common side effects associated with this
medicine include nose and throat infection, diarrhoea
and vomiting, headache, problems affecting the gums, small areas
of skin thickening (hyperkeratosis), rash, dryness and
inflammation of the skin (dermatitis), and hair loss
(alopecia)
A full list of side effects can be found in the Patient
Information Leaflet (PIL) or the Summary of Product
Characteristics (SmPC), which will be published on the MHRA
website within 7 days of approval.
Anyone who suspects they are having a side effect from this
medicine are encouraged to talk to their doctor, pharmacist or
nurse and report it directly to the Yellow Card scheme, either
through the website (https://yellowcard.mhra.gov.uk/)
or by searching the Google Play or Apple App stores for MHRA
Yellow Card.
Notes to editors
-
The new
marketing authorisation was granted on 20
February 2026 to Insmed Netherlands B.V.
-
More information can be found in the Summary of Product
Characteristics and Patient Information leaflets which will
be published on the MHRA Products
website within 7 days of approval.
-
For more information about bronchiectasis,
visit: Bronchiectasis -
NHS
